ALFA Finder| Revenue growth | FY26 revenue at ₹3,373 crores. |
|---|---|
| Margins | EBITDA margin increased to 18.6% from 5.4% three years prior. |
| Demand visibility | Significant unmet need in ICUs for carbapenem-resistant infections. |
| Management confidence | High; described Zaynich as a 'once-in-a-generation' opportunity. |
Growth
Top line ₹3,373cr; EBITDA ₹630cr (up 51%); PBT ₹238cr. EBITDA margins improved from 5.4% to 18.6% in three years.
Outlook
Guided capex of ₹200-300cr over 3 years. Zaynich peak sales potential estimated at $1.5B to $2B globally.
Risks
Execution challenges in building a new business model for novel drugs and navigating complex US market dynamics.
Last quarter's promises, checked
Delivered
- EBITDA growth >60% → delivered 51% (= PARTIAL)
- Net debt-to-equity 0.01% → delivered 0.1 (= MISS)
- ZAYNICH US launch FY26-27 → delivered US FDA approval FY26 (= BEAT)
Partly delivered
- EBITDA margin 14% → delivered 18.6% (= BEAT)
- Double capacity 24-36 months → delivered capex ₹200-300cr plan (= PARTIAL)
Missed
- Revenue growth 5% (FY25) → delivered 11.2% (FY26) (= BEAT)
- Net debt INR 64cr → delivered INR 337cr (implied) (= MISS)
Earnings Call filed with NSE, NSE: WOCKPHARMA. Summary written with AI assistance from the document.
Wockhardt Ltd: key numbers
- Share price
- ₹2,050.00
- Market cap
- ₹33,315 Cr
- Revenue (annual)
- ₹3,373 Cr
- Net profit (annual)
- ₹213.0 Cr
- P/E (TTM)
- 81.3×Sector 43.8×
- Promoter holding
- 49.32%+0.24% QoQ
- FII holding
- 7.02%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Wockhardt Ltd
All →Wockhardt Other Announcement
Wockhardt's monitoring agency report confirms no deviation in QIP proceeds use for the quarter ended September 30, 2026. It is routine periodic compliance with no financial event.
Wockhardt Management Change
Wockhardt designated Mr. Sumit Garg as Chief Digital & Information Officer, a Senior Management Personnel, from 02 November 2026. He brings over 30 years of technology and transformation leadership experience.
- Execution
- Full-time employment; term not time-bound
Wockhardt Results Update
Wockhardt reported Q2 FY27 PAT of Rs.73 Cr on revenue of Rs.969 Cr, up 24%. Biotech operations grew 68%, driven by emerging markets.
Wockhardt Q2 FY27 Results: Net Profit ₹73 Cr, Down 11.0% YoY
Wockhardt Ltd reported revenue from operations of ₹969 Cr (+23.9% YoY) and net profit of ₹73 Cr (-11.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹73 Cr · -11.0% YoY
Wockhardt Employee Stock Options
Wockhardt allotted 20,000 equity shares at Rs.5 exercise price under its ESOS 2011 scheme. Paid-up capital increases to 16,25,12,169 shares of Rs.5 each.
Wockhardt Board Meeting Date
Wockhardt Ltd intimated that its Board will meet on 2 Nov 2026 to approve Q1 FY27 unaudited results. The trading window remains closed until 48 hours post-declaration.